Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

REMEVi vs VigorMeds

REMEVi
Graded #70

Higher grade

vs+21.799999999999997
VigorMeds
Graded #483

Lower grade

The verdict

REMEVi takes it — 73.5/100 to 51.7/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +12
57
45
Dose & formulationREMEVi +43
83
40
Clinical oversightREMEVi +16
86
70
Labs & monitoringREMEVi +2
55
53
FulfillmentREMEVi +37
97
60
Contract termsREMEVi +28
69
41
REMEVi · left barVigorMeds · right bar

The numbers

MetricREMEViVigorMeds
WeighScore73.5/10051.7/100
GradeCC
Scorecard rank#70#483
Semaglutide$219/moNot disclosed
Tirzepatide$319/moNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
VigorMeds

Graded #483 · C

Strengths

  • Provider-guided GLP-1 weight management via a telehealth consultation, not a pure async questionnaire
  • Care delivered by named, experienced clinicians (Dr. Anthony Kane, Dr. Kevin Kargman, Stephanie Kowatch FNP-C)
  • No-questions-asked 30-day satisfaction guarantee
  • Multi-vertical platform — also offers anti-aging/wellness, ED, and hair-loss treatment
  • Personalized treatment plan with ongoing follow-up and support

Where it loses points

  • Pricing not shown until you create an account and complete the intake
  • Specific GLP-1 medications and forms are not named on the public site
  • States served are not listed on an accessible page
  • Vigormeds LLC is a patient-management platform; prescribing is via OLA Health LLC and independent providers
  • No LegitScript certification or pharmacy-partner details published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard